289 patents
Page 5 of 15
Utility
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
4 Oct 22
Ellen Filvaroff, Antonia Lopez-Girona, Gang Lu
Filed: 3 Apr 20
Utility
Substituted 4-AMINOISOINDOLINE-1,3-DIONE Compounds, Compositions Thereof, and Methods of Treatment Therewith
29 Sep 22
Matthew D. Alexander, Soraya Carrancio, Matthew D. Correa, Virginia Heather Sharron Grant, Joshua Hansen, Roy L. Harris, Dehua Huang, Timothy S. Kercher, Antonia Lopez-Girona, Mark A. Nagy, Veronique Plantevin-Krenitsky
Filed: 12 May 22
Utility
Solid Forms Comprising (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE and Salts Thereof, and Compositions Comprising and Methods of Using the Same
15 Sep 22
Provided herein are formulations, processes, solid forms and methods of use relating to salts of and solid forms comprising free base or salts of (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile.
Gerald D. Artman, III, Antonio C. Ferretti, Lianfeng Huang, Udaykumar Jain, Hon-Wah Man, Paula A. Tavares-Greco, Wenju Wu, Nancy Nienhua Tsou, Zhiwei Yin
Filed: 27 May 22
Utility
Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use
13 Sep 22
Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ε (CD3) provided herein, in treating, preventing or managing multiple myeloma.
Daniel W. Pierce, Lilly L. Wong
Filed: 22 May 19
Utility
Antiproliferative Compounds and Methods of Use Thereof
8 Sep 22
Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds.
Matthew D. Alexander, Gerald D. Artman, III, Gordon L. Bray, James Carmichael, Soraya Carrancio, Brian E. Cathers, Matthew D. Correa, Joshua Hansen, Courtney G. Havens, Timothy S. Kercher, Antonia Lopez-Girona, Xiaoling Lu, Hon-Wah Man, Mark A. Nagy, Rama K. Narla, Joseph R. Piccotti, Daniel W. Pierce, Paula A. Tavares-Greco, Brandon W. Whitefield, Lilly L. Wong, Nanfei Zou
Filed: 8 Nov 21
Utility
Methods of Treating Cancer by Targeting Cold Tumors
1 Sep 22
Methods are provided for the treatment of cancer or neoplastic diseases and the like, by administering 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluoro- benzonitrile (compound of Formula (I)) or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1) to patients in need thereof.
Ellen Filvaroff, Brian Fox, Ida Aronchik, Tracy Chow
Filed: 12 Jun 20
Utility
Antibodies with low immunogenicity and uses thereof
30 Aug 22
Provided herein are antibodies and antigen-binding fragments thereof with low or no immunogenicity in humans and optionally with desirable manufacturing properties.
Jeffrey C. Johnson, Lawrence Dearth, Haralambos Hadjivassiliou, Jeonghoon Sun, Kandasamy Hariharan
Filed: 5 Jul 17
Utility
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
23 Aug 22
Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
Philip Chamberlain, Brian E. Cathers, Antonia Lopez-Girona
Filed: 17 Apr 20
Utility
MK2 Inhibitors, the Synthesis Thereof, and Intermediates Thereto
18 Aug 22
The present disclosure provides novel synthetic intermediates useful in the synthesis of MK2 kinase inhibitors.
Alexander L. Ruchelman, John R. Coombs, Keming Zhu, Daniel Lim, Candice Lee Joe, David T. George, Bin Zheng, Dong Lin
Filed: 28 Jan 22
Utility
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
16 Aug 22
Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof.
Hon-Wah Man, Roger Shen-Chu Chen, George W. Muller, Alexander L. Ruchelman, Ehab M. Khalil, Weihong Zhang
Filed: 31 Mar 20
Utility
Azacitidine In Combination with Venetoclax, Gilteritinib, Midostaurin or Other Compounds for Treating Leukemia or Myelodysplastic Syndrome
11 Aug 22
Provided herein are methods for using 5-azacytidine in combination with one or more additional agents to treat diseases and disorders including acute myeloid or myelogenous leukemia (AML).
CL Beach, Diana R. Dunshee, Daniel E. Lopes de Menezes, Kyle MacBeth, Yumin Dai, Shelonitda Rose, Jessica Jang, Mark Frattini
Filed: 19 Jun 20
Utility
Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof
9 Aug 22
Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer.
G. Patrick Stahly, David Jonaitis, Ho-Wah Hui, Kevin J. Klopfer
Filed: 1 Oct 20
Utility
Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
2 Aug 22
Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.
Paul F. Fernandez, Antonio C. Ferretti, Ying Li, Weihong Zhang
Filed: 18 Mar 20
Utility
BCMA-binding antibodies and uses thereof
2 Aug 22
Antibody species that bind B-Cell Maturation Antigen (BCMA) are provided as well as methods of depleting BCMA-expressing cells in a patient in need thereof, comprising administering a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof.
Mahan Abbasian, Henry Chan, Kandasamy Hariharan, Jeonghoon Sun, Andrew Wurmser
Filed: 20 Feb 19
Utility
Methods for screening cereblon modifying compounds
2 Aug 22
A method of screening a cereblon modifying compound for treating a disease or disorder, comprising: obtaining a sample; determining a first protein level of SALL4; administering the cereblon modifying compound to the sample; determining a second protein level of SALL4; comparing the first level and the second protein level of SALL4 to determine if the cereblon modifying compound induces degradation of SALL4; and selecting the cereblon modifying compound that does not induce degradation of SALL4.
Mary Matyskiela, Philip Chamberlain, Suzana Sturlini Couto, Katherine Stamp, Philip J. Sherratt, Gang Lu, Julia Hui
Filed: 10 Jan 19
Utility
Methods of Synthesis of (1R,2R,5R)-5-AMINO-2-METHYL-CYCLOHEXANOL Hydrochloride and Intermediates Useful Therein
28 Jul 22
Provided herein are methods and intermediates for making (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride, which are useful for the preparation of compounds useful for the treatment of a disease, disorder, or condition associated with the JNK pathway.
Terrence Joseph CONNOLLY, Hon-Wah MAN, Periyandi NAGARAJAN, Chinnapillai RAJENDIRAN, Jasti VENKATESWARLU
Filed: 3 Nov 21
Utility
Tablet compositions
19 Jul 22
Provided herein is a tablet comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a pharmaceutically acceptable salt thereof.
Sreenivas S. Bhat, Scott Burnside, Darshan Parikh, Chong-Hui Gu, Syed Altaf
Filed: 6 Sep 17
Utility
Methods of treating non-Hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
19 Jul 22
Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.
Maria Soraya Carrancio Anton, Tonia J. Buchholz, Antonia Lopez-Girona, Rama Krishna Narla, Michael Pourdehnad
Filed: 9 Apr 20
Utility
Antiproliferative compounds, and their pharmaceutical compositions and uses
21 Jun 22
Compounds of formula A-I and B-I, compositions comprising the compounds, methods of making the compounds and methods of their uses are disclosed.
Matthew D. Alexander, Matthew D. Correa, Joshua Hansen, Raj Kumar Raheja, John Sapienza
Filed: 6 Mar 20
Utility
Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
14 Jun 22
Matthew D. Alexander, Soraya Carranclo, Matthew D. Correa, Virginia Heather Sharron Grant, Joshua Hansen, Roy L. Harris, Dehua Huang, Timothy S. Kercher, Antonia Lopez-Girona, Mark A. Nagy, Veronique Plantevin-Krenitsky
Filed: 22 Apr 19